Adaptive Biotechnologies Corp (ADPT)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $4.70B
Last updated: Nov 17, 2026 at 11:04 AM ET
Adaptive Biotechnologies Corp (ADPT) Stock Forecast
Analysts expect Adaptive Biotechnologies (ADPT) to earn -$0.37 per share in the fiscal year ending Dec 31, 2026, on revenue of $307.02M. Of 8 analysts, 8 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 8 ratings average 1.75, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 25.0% |
| Buy | 6 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 8
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 21.6%.
- Fiscal year ending Dec 31, 2026
- -$0.37
- EPS consensus, revenue $307.02M
- Fiscal year ending Dec 31, 2027
- -$0.03
- EPS consensus, revenue $373.34M
- Next report
- Feb 3, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.37 | -$0.37 to -$0.37 | 1 | $307.02M | $304.32M to $309.68M | 7 |
| Dec 31, 2027 | -$0.03 | -$0.08 to -$0.01 | 3 | $373.34M | $360.00M to $388.81M | 8 |
Quarterly Estimates
The EPS consensus falls from -$0.07 for the quarter ending Dec 31, 2026 to -$0.10 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.07 | -$0.08 to -$0.04 | 11 | $82.13M | $76.44M to $87.15M | 10 |
| Mar 31, 2027 | -$0.10 | -$0.10 to -$0.10 | 2 | $80.41M | $77.71M to $82.80M | 7 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 5 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.54.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.37 | -$0.54 | -$0.54 | -$0.54 | -$0.54 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.03 | -$0.18 | -$0.18 | -$0.18 | -$0.18 | N/A |
| Quarter ending Mar 31, 2027 | -$0.10 | -$0.10 | -$0.10 | -$0.10 | -$0.10 | N/A |
Frequently Asked Questions About ADPT
What is the ADPT stock forecast?
Consensus analyst estimates put Adaptive Biotechnologies's EPS at -$0.37 for the fiscal year ending Dec 31, 2026, on revenue of $307.02M. The consensus rating from 8 analysts is Buy.
How do analysts rate ADPT stock?
Of 8 analysts covering Adaptive Biotechnologies, 2 rate it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ADPT next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.37, with estimates from -$0.37 to -$0.37 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.03, with estimates from -$0.08 to -$0.01 from 3 analysts.
What revenue do analysts expect from Adaptive Biotechnologies next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $307.02M, with estimates from $304.32M to $309.68M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $373.34M, with estimates from $360.00M to $388.81M.
How many analysts cover ADPT?
8 analysts rate Adaptive Biotechnologies stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
ADPT pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts